Should I buy or sell Liquidia stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LQDA shares. View LQDA analyst ratings or view top-rated stocks .

What is Liquidia's stock price target for 2024?

5 equities research analysts have issued 12 month target prices for Liquidia's shares. Their LQDA share price targets range from $3.00 to $32.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price. View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts .

How have LQDA shares performed in 2024?

Liquidia's stock was trading at $12.03 at the beginning of 2024. Since then, LQDA shares have increased by 15.2% and is now trading at $13.86. View the best growth stocks for 2024 here .

When is Liquidia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LQDA earnings forecast .

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) issued its earnings results on Wednesday, March, 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.19. The company earned $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative trailing twelve-month return on equity of 132.16%.

What ETFs hold Liquidia's stock?

ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What other stocks do shareholders of Liquidia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV) , OPKO Health (OPK) , Aldeyra Therapeutics (ALDX) , Sorrento Therapeutics (SRNE) , vTv Therapeutics (VTVT) , Genocea Biosciences (GNCA) , Inovio Pharmaceuticals (INO) , AbbVie (ABBV) , Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA) .

When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LQDA

Liquidia (LQDA) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free LQDA Stock Alerts

$13.86

+0.28 (+2.06%)

(As of 04/17/2024 ET)

Compare

Today's Range: $13.32
▼
$13.90
50-Day Range: $13.58
▼
$16.73
52-Week Range: $5.71
▼
$16.99

Volume: 658,239 shs
Average Volume: 947,129 shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get Liquidia alerts:

Liquidia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 51.5% Upside
$21.00 Price Target
Short Interest: Bearish
9.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.74
Based on 10 Articles This Week
Insider Trading: Selling Shares
$1.08 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.01) to ($0.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

508th out of 914 stocks

Biotechnology Industry

28th out of 52 stocks

3.3

Analyst's Opinion

Consensus Rating
Liquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Liquidia has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.77% of the outstanding shares of Liquidia have been sold short.
Short Interest Ratio / Days to Cover
Liquidia has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Liquidia has recently increased by 2.34%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Liquidia does not currently pay a dividend.
Dividend Growth
Liquidia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LQDA.

2.6

News and Social Media Coverage

News Sentiment
Liquidia has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Liquidia this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,077,886.00 in company stock.
Percentage Held by Insiders
31.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Liquidia are expected to grow in the coming year, from ($1.01) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Liquidia is -11.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Liquidia is -11.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Liquidia has a P/B Ratio of 18.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Liquidia Stock (NASDAQ:LQDA)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

LQDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LQDA Stock News Headlines

April 16, 2024 | insidertrades.com

Jason Adair Sells 1,189 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

March 20, 2024 | insidertrades.com

Jason Adair Sells 4,657 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 20, 2024 | insidertrades.com

Insider Selling: Liquidia Co. (NASDAQ:LQDA) CEO Sells 28,583 Shares of Stock

April 16, 2024 | americanbankingnews.com

Liquidia Co. (NASDAQ:LQDA) Insider Jason Adair Sells 1,189 Shares of Stock

April 11, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Liquidia (NASDAQ:LQDA)

April 3, 2024 | finance.yahoo.com

Liquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stake

April 2, 2024 | globenewswire.com

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 1, 2024 | markets.businessinsider.com

Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ Yutrepia

April 1, 2024 | marketwatch.com

Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling

April 1, 2024 | globenewswire.com

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

March 29, 2024 | bizjournals.com

Morrisville firm wins in federal court, targets FDA approval

March 28, 2024 | msn.com

Liquidia gains after court win in patent dispute with United Therapeutics

March 21, 2024 | investing.com

Liquidia Corp CEO sells over $450k in company stock

March 21, 2024 | investing.com

Liquidia Corp CMO sells over $119k in company stock

March 20, 2024 | finance.yahoo.com

Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA)

March 20, 2024 | finance.yahoo.com

Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA)

March 16, 2024 | finance.yahoo.com

LQDA Apr 2024 7.500 call

March 15, 2024 | seekingalpha.com

Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Liquidia Technologies with Doubling Price Target on Yutrepia’s Promising Prospects

March 14, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Legend Biotech (LEGN)

March 14, 2024 | finance.yahoo.com

Liquidia Full Year 2023 Earnings: Misses Expectations

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Liquidia Technologies Amid Favorable Legal Rulings and Yutrepia’s Market Potential

March 13, 2024 | markets.businessinsider.com

Unveiling 6 Analyst Insights On Liquidia

March 13, 2024 | finance.yahoo.com

Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results

March 13, 2024 | globenewswire.com

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive LQDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:LQDA
CUSIP: N/A
CIK: 1819576
Web: www.liquidia.com
Phone: (919) 328-4400
Fax: N/A
Employees: 145
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $32.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +51.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,500,000.00
Net Margins: -448.89%
Pretax Margin: -448.89%
Return on Equity: -132.16%
Return on Assets: -65.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.85
Quick Ratio: 4.85

Sales & Book Value

Annual Sales: $17.49 million
Price / Sales: 60.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 18.99

Miscellaneous

Outstanding Shares: 76,030,000
Free Float: 52,003,000
Market Cap: $1.05 billion
Optionable: Optionable
Beta: 0.16

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Roger A. Jeffs Ph.D. (Age 62)
CEO & Director
Comp: $532.23k
Mr. Michael Kaseta (Age 47)
COO & CFO
Comp: $627.85k
Mr. Russell Schundler (Age 49)
General Counsel & Corporate Secretary
Comp: $541.92k
Mr. William R. Kenan Jr.
Co-Founder
Dr. Ginger Denison
Co-Founder
Jennifer Almond
Director of Investor Relations & Corporate Communications
Ms. Sarah Krepp SPHR
Vice President of People & Culture
Mr. Jason Adair (Age 50)
Chief Business Officer
Dr. Tushar Shah M.D. (Age 63)
Senior Vice President of Product Development
Comp: $792.36k
Mr. Scott Moomaw (Age 53)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LQDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Liquidia stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LQDA shares.
View LQDA analyst ratings or view top-rated stocks.
What is Liquidia's stock price target for 2024?: 5 equities research analysts have issued 12 month target prices for Liquidia's shares. Their LQDA share price targets range from $3.00 to $32.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price.
View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts.
How have LQDA shares performed in 2024?: Liquidia's stock was trading at $12.03 at the beginning of 2024. Since then, LQDA shares have increased by 15.2% and is now trading at $13.86.
View the best growth stocks for 2024 here.
When is Liquidia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LQDA earnings forecast.
How were Liquidia's earnings last quarter?: Liquidia Co. (NASDAQ:LQDA) issued its earnings results on Wednesday, March, 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.19. The company earned $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative trailing twelve-month return on equity of 132.16%.

What ETFs hold Liquidia's stock?: ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What other stocks do shareholders of Liquidia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).
When did Liquidia IPO?: Liquidia (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
How do I buy shares of Liquidia?: Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LQDA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial